Association of the PGC-1α rs8192678 variant with microalbuminuria in subjects with type 2 diabetes mellitus

Disease Markers

Volumn 32, Issue 6, 2012, Pages 363-369

  Prior, Sarah L ^a   Clark, Amy R ^a   Jones, Danielle A ^a   Bain, Steve C ^a   Hurel, Steve J ^b   Humphries, Steve E ^c   Stephens, Jeffrey W ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

microalbuminuria; oxidative stress; PGC 1 ; type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA;

AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ETHNIC DIFFERENCE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; URINARY EXCRETION;

EID: 84862879019     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2012/416138     Document Type: Article

References (45)

1. Cooke, J.P., The endothelium: a new target for therapy. Vascular Medicine. 2000; 5(1): 49-53.
2. Heitzer, T., et al., Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001; 104(22): 2673-8.
3. Endemann, D.H. and Schiffrin, E.L. Endothelial dysfunction. J Am Soc Nephrol. 2004; 15(8): 1983-92.
4. Rytand, D.A., The significance of albuminuria; proteinuria. Calif Med. 1949; 70(3): 174-6.
5. Atkins, R.C., et al., Association between albuminuria and proteinuria in the general population: the AusDiab Study. Nephrol Dial Transplant. 2003; 18(10): 2170-4.
6. Navarro-Gonzalez, J.F. and Mora-Fernandez, C. The Role of Inflammatory Cytokines in Diabetic Nephropathy. J Am Soc Nephrol. 2008; 19(3): 433-442.
7. Gall, M.A., et al., Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995; 44(11): 1303-9.
8. Ek, J., et al., Mutation analysis of peroxisome proliferatoractivated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia. 2001; 44(12): 2220-6.
9. Choi, Y.S., et al., Impaired coactivator activity of the Gly482 variant of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) on mitochondrial transcription factor A (Tfam) promoter. Biochem Biophys Res Commun. 2006; 344(3): 708-12.
10. Rhee, J., et al., Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci USA. 2003; 100(7): 4012-7.
11. Lai, C.Q., et al., PPARGC1A variation associated with DNA damage, diabetes, and cardiovascular diseases: the Boston Puerto Rican Health Study. Diabetes. 2008; 57(4): 809-16.
12. Hara, K., et al., A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia. 2002; 45(5): 740-3.
13. Nitz, I., et al., Analysis of PGC-1alpha variants Gly482Ser and Thr612Met concerning their PPARgamma2-coactivation function. Biochem Biophys Res Commun. 2007; 353(2): 481-6.
14. Vimaleswaran, K.S., et al., Peroxisome proliferator-activated receptor-gamma co-activator-1alpha (PGC-1alpha) gene polymorphisms and their relationship to Type 2 diabetes in Asian Indians. Diabet Med. 2005; 22(11): 1516-21.
15. Casteilla, L., M. Rigoulet and Penicaud, L. Mitochondrial ROS metabolism: modulation by uncoupling proteins. IUBMB Life. 2001; 52(3-5): 181-8.
16. Negre-Salvayre, A., et al., A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation. Faseb J. 1997; 11(10): 809-15.
17. Dhamrait, S.S., et al., Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. Eur Heart J. 2004; 25(6): 468-75.
18. Cheurfa, N., et al., The Gly482Ser polymorphism in the peroxisome proliferator-activated receptor-gamma coactivator-1 gene is associated with hypertension in type 2 diabetic men. Diabetologia. 2004; 47(11): 1980-3.
19. Ling, C., et al., Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J Clin Invest. 2004; 114(10): 1518-26.
20. Andrulionyte, L., et al., Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia. 2004; 47(12): 2176-84.
21. Fanelli, M., et al., The Gly482Ser missense mutation of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) gene associates with reduced insulin sensitivity in normal and glucose-intolerant obese subjects. Dis Markers. 2005; 21(4): 175-80.
22. Deeb, S.S. and Brunzell, J.D. The Role of the PGC1alpha Gly482Ser Polymorphism in Weight Gain due to Intensive Diabetes Therapy. PPAR Res. 2009; 2009: 649286.
23. Kunej, T., et al., A Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene is associated with type 2 diabetes in Caucasians. Folia Biol (Praha). 2004; 50(5): 157-8.
24. Gayathri, S.B., et al., Association of the PPARGC1A gene polymorphism with diabetic nephropathy in an Asian Indian population (CURES-41). Metab Syndr Relat Disord. 8(2): 119-26.
25. Jung L, S.J., Kim M., Chung K., Moon J.Y., Lee S., Lee T. and Lim C. The Polymorphisms of PPAR-gamma Coactivator 1alpha Gly482Ser (PGC-1alpha Gly482Ser) are Associated with the Nephropathy ofKorean Patients with Type 2Diabetes Mellitus. The Korean Journal of Nephrology. 2006; 25(5): 753-759.
26. Stephens, J.W., et al., Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil. 2004; 11(6): 521-8.
27. Alberti, K.G. and Zimmet, P.Z. New diagnostic criteria and classification of diabetes-again? Diabet Med. 1998; 15(7): 535-6.
28. Amin, R., et al., Longitudinal relation between limited joint mobility, height, insulin-like growth factor 1 levels, and risk of developing microalbuminuria: the Oxford Regional Prospective Study. Arch Dis Child. 2005; 90(10): 1039-44.
29. Amin, R., et al., The development of microalbuminuria is associated with raised longitudinal adiponectin levels in female but not male adolescent patients with type 1 diabetes. Diabetologia. 2008; 51(9): 1707-13.
30. Magliano, D.J., et al., HPLC-detected albuminuria predicts mortality. J Am Soc Nephrol. 2007; 18(12): 3171-6.
31. Sampson, M.J., et al., Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care. 2002; 25(3): 537-41.
32. Stephens, J.W., et al., Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males. Clin Chem. 2006; 52(3): 446-52.
33. Friedlander, Y., et al., Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis. 2000; 148(1): 141-9.
34. Belo, L., et al., Changes in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis. 2002; 162(2): 425-32.
35. Schalkwijk, C.G., et al., Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999; 42(3): 351-7.
36. Hidaka, A., et al., Decrease in the particle size of low-density lipoprotein (LDL) by oxidation. Bioorg Med Chem Lett. 2005. 15(11): 2781-5.
37. Ujihara, N., et al., Association between plasma oxidized lowdensity lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract. 2002; 58(2): 109-14.
38. Austin, M.A., et al., Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction. JAMA: The Journal of the American Medical Association. 1988; 260(13): 1917-1921.
39. Berneis, K.K. and Krauss, R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002; 43(9): 1363-79.
40. Blake, G.J., et al., Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002; 106(15): 1930-7.
41. Vakkilainen, J., et al., Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107(13): 1733-7.
42. Stephens, J.W., M.P. Khanolkar and Bain, S.C. The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis. 2009; 202(2): 321-9.
43. Risch, N.J., Searching for genetic determinants in the new millennium. Nature. 2000; 405(6788): 847-56.
44. Sing, C.F., J.H. Stengard andKardia, S.L. Genes, environment, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003; 23(7): 1190-6.
45. Stephens, J.W., S.C. Bain and Humphries, S.E. Geneenvironment interaction and oxidative stress in cardiovascular disease. Atherosclerosis. 2008; 200(2): 229-38.